5岁以下严重急性营养不良住院儿童结核病筛查和诊断的治疗决策算法:成本效益分析

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
EClinicalMedicine Pub Date : 2025-04-19 eCollection Date: 2025-05-01 DOI:10.1016/j.eclinm.2025.103206
Marc d'Elbée, Nyashadzaishe Mafirakureva, Chishala Chabala, Minh Huyen Ton Nu Nguyet, Martin Harker, Clémentine Roucher, Gerald Businge, Perfect Shankalala, Bwendo Nduna, Veronica Mulenga, Maryline Bonnet, Eric Wobudeya, Olivier Marcy, Peter J Dodd
{"title":"5岁以下严重急性营养不良住院儿童结核病筛查和诊断的治疗决策算法:成本效益分析","authors":"Marc d'Elbée, Nyashadzaishe Mafirakureva, Chishala Chabala, Minh Huyen Ton Nu Nguyet, Martin Harker, Clémentine Roucher, Gerald Businge, Perfect Shankalala, Bwendo Nduna, Veronica Mulenga, Maryline Bonnet, Eric Wobudeya, Olivier Marcy, Peter J Dodd","doi":"10.1016/j.eclinm.2025.103206","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Children with severe acute malnutrition (SAM) are an important risk group for underdiagnosis and death from tuberculosis. In 2022, the World Health Organization (WHO) recommended use of treatment decision algorithms (TDAs) for tuberculosis diagnosis in children. There is currently no cost-effectiveness evidence for TDA-based approaches compared to routine practice.</p><p><strong>Methods: </strong>The TB-Speed SAM study developed i) a one-step TDA including Xpert, clinical, radiological and echography features, and ii) a two-step TDA, which also included a screening phase, for children under 5 years hospitalised with SAM at three tertiary hospitals in Uganda and Zambia from 4th November 2019 to 20th June 2022. This study is registered with ClinicalTrials.gov, NCT04240990. We assessed the diagnostic accuracy and cost-effectiveness of deploying TB-Speed and WHO TDA-based approaches compared to the standard of care (SOC). Estimated outcomes included children started on tuberculosis treatment, false positive rates, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (ICERs).</p><p><strong>Findings: </strong>Per 100 children hospitalised with SAM, averaging 19 children with tuberculosis, the one-step TDA initiated 17 true positive children (95% uncertainty intervals [UI]: 12-23) on tuberculosis treatment, the two-step TDA 15 (95%UI: 10-22), the WHO TDA 14 (95%UI: 9-19), and SOC 4 (95%UI: 2-9). The WHO TDA generated the most false positives (35, 95%UI: 24-46), followed by the one-step TDA (18, 95%UI: 6-29), the two-step TDA (14, 95%UI: 1-25), and SOC (11, 95%UI: 3-17). All TDA-based approaches had ICERs below plausible country cost-effectiveness thresholds compared to SOC (one-step: $44-51/DALY averted, two-step: $34-39/DALY averted, WHO: $40-46/DALY averted).</p><p><strong>Interpretation: </strong>Our findings show that these TDA-based approaches are highly cost-effective for the vulnerable group of children hospitalised with SAM, compared to current practice.</p><p><strong>Funding: </strong>Unitaid Grant number: 2017-15-UBx-TB-SPEED.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"83 ","pages":"103206"},"PeriodicalIF":9.6000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033959/pdf/","citationCount":"0","resultStr":"{\"title\":\"Treatment decision algorithms for tuberculosis screening and diagnosis in children below 5 years hospitalised with severe acute malnutrition: a cost-effectiveness analysis.\",\"authors\":\"Marc d'Elbée, Nyashadzaishe Mafirakureva, Chishala Chabala, Minh Huyen Ton Nu Nguyet, Martin Harker, Clémentine Roucher, Gerald Businge, Perfect Shankalala, Bwendo Nduna, Veronica Mulenga, Maryline Bonnet, Eric Wobudeya, Olivier Marcy, Peter J Dodd\",\"doi\":\"10.1016/j.eclinm.2025.103206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Children with severe acute malnutrition (SAM) are an important risk group for underdiagnosis and death from tuberculosis. In 2022, the World Health Organization (WHO) recommended use of treatment decision algorithms (TDAs) for tuberculosis diagnosis in children. There is currently no cost-effectiveness evidence for TDA-based approaches compared to routine practice.</p><p><strong>Methods: </strong>The TB-Speed SAM study developed i) a one-step TDA including Xpert, clinical, radiological and echography features, and ii) a two-step TDA, which also included a screening phase, for children under 5 years hospitalised with SAM at three tertiary hospitals in Uganda and Zambia from 4th November 2019 to 20th June 2022. This study is registered with ClinicalTrials.gov, NCT04240990. We assessed the diagnostic accuracy and cost-effectiveness of deploying TB-Speed and WHO TDA-based approaches compared to the standard of care (SOC). Estimated outcomes included children started on tuberculosis treatment, false positive rates, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (ICERs).</p><p><strong>Findings: </strong>Per 100 children hospitalised with SAM, averaging 19 children with tuberculosis, the one-step TDA initiated 17 true positive children (95% uncertainty intervals [UI]: 12-23) on tuberculosis treatment, the two-step TDA 15 (95%UI: 10-22), the WHO TDA 14 (95%UI: 9-19), and SOC 4 (95%UI: 2-9). The WHO TDA generated the most false positives (35, 95%UI: 24-46), followed by the one-step TDA (18, 95%UI: 6-29), the two-step TDA (14, 95%UI: 1-25), and SOC (11, 95%UI: 3-17). All TDA-based approaches had ICERs below plausible country cost-effectiveness thresholds compared to SOC (one-step: $44-51/DALY averted, two-step: $34-39/DALY averted, WHO: $40-46/DALY averted).</p><p><strong>Interpretation: </strong>Our findings show that these TDA-based approaches are highly cost-effective for the vulnerable group of children hospitalised with SAM, compared to current practice.</p><p><strong>Funding: </strong>Unitaid Grant number: 2017-15-UBx-TB-SPEED.</p>\",\"PeriodicalId\":11393,\"journal\":{\"name\":\"EClinicalMedicine\",\"volume\":\"83 \",\"pages\":\"103206\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033959/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EClinicalMedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.eclinm.2025.103206\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103206","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:严重急性营养不良(SAM)儿童是结核病诊断不足和死亡的重要危险群体。2022年,世界卫生组织(世卫组织)建议将治疗决策算法(tda)用于儿童结核病诊断。与常规做法相比,目前尚无基于tda的方法的成本效益证据。方法:TB-Speed SAM研究针对2019年11月4日至2022年6月20日期间在乌干达和赞比亚三家三级医院因SAM住院的5岁以下儿童制定了i)一步TDA,包括Xpert、临床、放射学和超声特征;ii)两步TDA,其中还包括筛查阶段。本研究已在ClinicalTrials.gov注册,编号NCT04240990。与标准护理(SOC)相比,我们评估了部署TB-Speed和WHO tda为基础的方法的诊断准确性和成本效益。估计结果包括儿童开始接受结核病治疗、假阳性率、残疾调整生命年(DALYs)和增量成本-效果比(ICERs)。结果:每100名住院的SAM儿童中,平均有19名结核病儿童,一步TDA启动了17名真阳性儿童(95%不确定区间[UI]: 12-23)的结核病治疗,两步TDA 15 (95%UI: 10-22), WHO TDA 14 (95%UI: 9-19), SOC 4 (95%UI: 2-9)。WHO TDA产生的假阳性最多(35,95%UI: 24-46),其次是一步TDA (18, 95%UI: 6-29)、两步TDA (14, 95%UI: 1-25)和SOC (11, 95%UI: 3-17)。与SOC相比,所有基于tda的方法的ICERs均低于合理的国家成本效益阈值(一步:44-51美元/避免DALY,两步:34-39美元/避免DALY, WHO: 40-46美元/避免DALY)。解释:我们的研究结果表明,与目前的做法相比,这些以tda为基础的方法对患有SAM住院的弱势儿童群体具有很高的成本效益。资助:国际药品采购机制资助号:2017-15-UBx-TB-SPEED。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment decision algorithms for tuberculosis screening and diagnosis in children below 5 years hospitalised with severe acute malnutrition: a cost-effectiveness analysis.

Background: Children with severe acute malnutrition (SAM) are an important risk group for underdiagnosis and death from tuberculosis. In 2022, the World Health Organization (WHO) recommended use of treatment decision algorithms (TDAs) for tuberculosis diagnosis in children. There is currently no cost-effectiveness evidence for TDA-based approaches compared to routine practice.

Methods: The TB-Speed SAM study developed i) a one-step TDA including Xpert, clinical, radiological and echography features, and ii) a two-step TDA, which also included a screening phase, for children under 5 years hospitalised with SAM at three tertiary hospitals in Uganda and Zambia from 4th November 2019 to 20th June 2022. This study is registered with ClinicalTrials.gov, NCT04240990. We assessed the diagnostic accuracy and cost-effectiveness of deploying TB-Speed and WHO TDA-based approaches compared to the standard of care (SOC). Estimated outcomes included children started on tuberculosis treatment, false positive rates, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (ICERs).

Findings: Per 100 children hospitalised with SAM, averaging 19 children with tuberculosis, the one-step TDA initiated 17 true positive children (95% uncertainty intervals [UI]: 12-23) on tuberculosis treatment, the two-step TDA 15 (95%UI: 10-22), the WHO TDA 14 (95%UI: 9-19), and SOC 4 (95%UI: 2-9). The WHO TDA generated the most false positives (35, 95%UI: 24-46), followed by the one-step TDA (18, 95%UI: 6-29), the two-step TDA (14, 95%UI: 1-25), and SOC (11, 95%UI: 3-17). All TDA-based approaches had ICERs below plausible country cost-effectiveness thresholds compared to SOC (one-step: $44-51/DALY averted, two-step: $34-39/DALY averted, WHO: $40-46/DALY averted).

Interpretation: Our findings show that these TDA-based approaches are highly cost-effective for the vulnerable group of children hospitalised with SAM, compared to current practice.

Funding: Unitaid Grant number: 2017-15-UBx-TB-SPEED.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信